Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Comparative outcome analyses of stromal vascular fraction vs nanofat in primary osteoarthritis knee: A double-blinded randomized controlled trial protocol.

Jeyaraman N., Shrivastava S., Rangarajan RV., Nallakumarasamy A., Ramasubramanian S., Muthu S.

Randomized Controlled Trial with a reported sample of 30 on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, published in World J Exp Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
World J Exp Med (2025)
Country
United States
Reported sample size
30
Source database
PubMed
PMID
41523762
PMCID
PMC12781693
DOI
10.5493/wjem.v15.i3.105973

Abstract (original English)

Background Osteoarthritis (OA) of the knee is a prevalent degenerative joint disease that significantly impairs quality of life and functional mobility. Emerging regenerative therapies, such as stromal vascular fraction (SVF) and nanofat, have demonstrated potential in cartilage repair and symptom alleviation. However, comparative clinical evidence evaluating their efficacy and safety remains limited. Aim To compare the clinical outcomes of SVF vs nanofat therapy in patients with primary knee OA. Methods Conducted at Mother Cell Regenerative Centre, Trichy, over 18 months (June 2025 to December 2026), the study will enroll 30 patients, randomly assigned to two groups of 15 each. Both interventions will be administered as a single intra-articular injection under sterile conditions, with cell viability (> 85%) confirmed by a standardized assay. Group A will receive autologous SVF injections, while Group B will receive autologous nanofat injections. The primary outcome measure is the change in pain scores at 12 months using the visual analog scale (VAS). Secondary outcomes include functional improvement assessed by Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities (WOMAC), and International Knee Documentation Committee (IKDC) scores, cartilage regeneration evaluated via magnetic resonance imaging with colour coded mapping of the cartilage volume (MR ca

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research